Reset filter
Mots-clés
Polyarthritis, primaer chronische ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

243 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 4; 5; 6; 7; 8; 9 - Administrative; Pain Assessment VAS Score; Patient's Global Assessment of Arthritis Condition VAS Score; Physician's Global Assessment of Arthritis Condition VAS Score

- 23/03/2020 - 1 Formulaire, 4 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Administrative, Pain Assessment VAS Score, Patient's Global Assessment of Arthritis Condition VAS Score , Physician's Global Assessment of Arthritis Condition VAS Score
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 3 - Vital Signs; Electronically Transferred Lab Data; PK Blood Sample; Investigational Product IV Dosing; Liver Event Assessment

- 23/03/2020 - 1 Formulaire, 9 Groupes Item, 36 Eléments de données, 1 Langue
Groupes Item: Administrative, Vital Signs - Prior to Infusion, Electronically Transferred Lab Data , PK Blood Sample - Before Infusion, PK Blood Sample - End of Infusion, PK Type Code, Investigational Product - IV Dosing, Total Volume of Infusion unit , Liver Event Assessment
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 2 - Biomarker Samples; Pharmacogenetic Research Consent; Transcriptomic Research Sample Collection Details; PK Blood Sample; Vital Signs; Investigational Product IV Dosing

- 18/03/2020 - 1 Formulaire, 9 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: Biomarker Samples, Pharmacogenetic Research Consent/ Blood Sample Collection, Transcriptomic Research Sample Collection Details, PK Blood Sample - Before Infusion, PK Blood Sample - End of Infusion, PK Type Code, Vital Signs, Investigational Product - IV Dosing, Total Volume of Infusion unit
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 2 - Run-In Failure; Randomisation Number; Electronically Transferred Lab Data; Liver Assessment

- 18/03/2020 - 1 Formulaire, 4 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Run-In Failure, Randomisation Number, Electronically Transferred Lab Data , Liver Event Assessment
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 2 - Pain Assessment VAS Score; Patient's Global Assessment of Arthritis Condition VAS Score; Physician's Global Assessment of Arthritis Condition VAS Score

- 18/03/2020 - 1 Formulaire, 3 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Pain Assessment VAS Score, Patient's Global Assessment of Arthritis Condition VAS Score , Physician's Global Assessment of Arthritis Condition VAS Score
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Visit 2 - Tender Joint Count; Swollen Joint Count; Swollen/Tender Joint Count; ESR

- 18/03/2020 - 1 Formulaire, 11 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Administrative, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Swollen/ Tender Joint Count, ESR - Local Laboratory
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Biomarker Samples; Diagnosis/ History of Rheumatoid Arthritis; Prior Methotrexate Treatment; Prior RA Medications; Screen Failure

- 17/03/2020 - 1 Formulaire, 7 Groupes Item, 31 Eléments de données, 1 Langue
Groupes Item: Biomarker Samples, Diagnosis/ History of Rheumatoid Arthritis, Prior Methotrexate Treatment, Prior Methotrexate Treatment , Prior RA Medications, Prior RA Medications , Screen Failure
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Chest X-Ray; Tender Joint Count; Swollen Joint Count; Electronically Transferred Lab Data; ESR

- 17/03/2020 - 1 Formulaire, 11 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Chest X-Ray, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Electronically Transferred Lab Data, ESR - Local Laboratory
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Vital Signs; Medical Conditions; Eligibility Question; Neurological Examination; ECG

- 17/03/2020 - 1 Formulaire, 5 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Vital Signs, Medical Conditions, Eligibility Question, Neurologic Examination, ECG
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Administrative; Patient's Global Assessment of Arthritis Condition VAS Score; Demography

- 17/03/2020 - 1 Formulaire, 6 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inform Screening, Inform Enrollment, Date of Visit/ Assessment, Subject Identification, Patient's Global Assessment of Arthritis Condition VAS Score, Demography
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT01667458

- 09/02/2020 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab); ODM derived from: https://clinicaltrials.gov/show/NCT01667458

Eligibility Early Rheumatoid Arthritis NCT01185301

- 08/12/2019 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA); ODM derived from: https://clinicaltrials.gov/show/NCT01185301

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial